Cargando…
Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer
Interactions between sialylated glycans and sialic acid-binding immunoglobulin-like lectin (Siglec) receptors have been recently described as potential new immune checkpoint that can be targeted to improve anticancer immunity. Myeloid cells have been reported to express a wide range of different Sig...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927547/ https://www.ncbi.nlm.nih.gov/pubmed/35309936 http://dx.doi.org/10.3389/fcell.2022.828916 |
_version_ | 1784670466613444608 |
---|---|
author | Wang, Jinyu Manni, Michela Bärenwaldt, Anne Wieboldt, Ronja Kirchhammer, Nicole Ivanek, Robert Stanczak, Michal Zippelius, Alfred König, David Rodrigues Manutano, Natalia Läubli, Heinz |
author_facet | Wang, Jinyu Manni, Michela Bärenwaldt, Anne Wieboldt, Ronja Kirchhammer, Nicole Ivanek, Robert Stanczak, Michal Zippelius, Alfred König, David Rodrigues Manutano, Natalia Läubli, Heinz |
author_sort | Wang, Jinyu |
collection | PubMed |
description | Interactions between sialylated glycans and sialic acid-binding immunoglobulin-like lectin (Siglec) receptors have been recently described as potential new immune checkpoint that can be targeted to improve anticancer immunity. Myeloid cells have been reported to express a wide range of different Siglecs; however, their expression and functions on cancer-associated dendritic cells (DCs) were not fully characterized. We found that classical conventional DCs (cDCs) from cancer patient samples have a high expression of several inhibitory Siglecs including Siglec-7, Siglec-9, and Siglec-10. In subcutaneous murine tumor models, we also found an upregulation of the inhibitory Siglec-E receptor on cancer-associated cDCs. DC lines and bone marrow-derived DCs (BMDCs) with expression of these inhibitory Siglecs showed impaired maturation states on transcriptome and protein level. Furthermore, ablation of these inhibitory Siglecs from DCs enhanced their capability to prime antigen-specific T cells and induce proliferation. Our work provides a deeper understanding of the influence of inhibitory Siglecs on DCs and reveals a potential new target to improve cancer immunotherapy. |
format | Online Article Text |
id | pubmed-8927547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89275472022-03-18 Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer Wang, Jinyu Manni, Michela Bärenwaldt, Anne Wieboldt, Ronja Kirchhammer, Nicole Ivanek, Robert Stanczak, Michal Zippelius, Alfred König, David Rodrigues Manutano, Natalia Läubli, Heinz Front Cell Dev Biol Cell and Developmental Biology Interactions between sialylated glycans and sialic acid-binding immunoglobulin-like lectin (Siglec) receptors have been recently described as potential new immune checkpoint that can be targeted to improve anticancer immunity. Myeloid cells have been reported to express a wide range of different Siglecs; however, their expression and functions on cancer-associated dendritic cells (DCs) were not fully characterized. We found that classical conventional DCs (cDCs) from cancer patient samples have a high expression of several inhibitory Siglecs including Siglec-7, Siglec-9, and Siglec-10. In subcutaneous murine tumor models, we also found an upregulation of the inhibitory Siglec-E receptor on cancer-associated cDCs. DC lines and bone marrow-derived DCs (BMDCs) with expression of these inhibitory Siglecs showed impaired maturation states on transcriptome and protein level. Furthermore, ablation of these inhibitory Siglecs from DCs enhanced their capability to prime antigen-specific T cells and induce proliferation. Our work provides a deeper understanding of the influence of inhibitory Siglecs on DCs and reveals a potential new target to improve cancer immunotherapy. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927547/ /pubmed/35309936 http://dx.doi.org/10.3389/fcell.2022.828916 Text en Copyright © 2022 Wang, Manni, Bärenwaldt, Wieboldt, Kirchhammer, Ivanek, Stanczak, Zippelius, König, Rodrigues Manutano and Läubli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Wang, Jinyu Manni, Michela Bärenwaldt, Anne Wieboldt, Ronja Kirchhammer, Nicole Ivanek, Robert Stanczak, Michal Zippelius, Alfred König, David Rodrigues Manutano, Natalia Läubli, Heinz Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer |
title | Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer |
title_full | Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer |
title_fullStr | Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer |
title_full_unstemmed | Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer |
title_short | Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer |
title_sort | siglec receptors modulate dendritic cell activation and antigen presentation to t cells in cancer |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927547/ https://www.ncbi.nlm.nih.gov/pubmed/35309936 http://dx.doi.org/10.3389/fcell.2022.828916 |
work_keys_str_mv | AT wangjinyu siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT mannimichela siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT barenwaldtanne siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT wieboldtronja siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT kirchhammernicole siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT ivanekrobert siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT stanczakmichal siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT zippeliusalfred siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT konigdavid siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT rodriguesmanutanonatalia siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer AT laubliheinz siglecreceptorsmodulatedendriticcellactivationandantigenpresentationtotcellsincancer |